Adams Daniel L, Adams Diane K, Alpaugh R Katherine, Cristofanilli Massimo, Martin Stuart S, Chumsri Saranya, Tang Cha-Mei, Marks Jeffrey R
Creatv MicroTech, Inc., Monmouth Junction, New Jersey.
Rutgers, The State University of New Jersey, New Brunswick, New Jersey.
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1037-42. doi: 10.1158/1055-9965.EPI-15-1221. Epub 2016 May 17.
Blood-based testing can be used as a noninvasive method to recover and analyze circulating tumor-derived cells for clinical use. Circulating cancer-associated macrophage-like cells (CAML) are specialized myeloid cells found in peripheral blood and associated with the presence of solid malignancies. We measured CAMLs prospectively in peripheral blood to ascertain their prevalence, specificity, and sensitivity in relation to breast disease status at clinical presentation.
We report on two related but separate studies: 1) CellSieve microfilters were used to isolate CAMLs from blood samples of patients with known malignant disease (n = 41). Prevalence and specificity was compared against healthy volunteers (n = 16). 2) A follow-up double-blind pilot study was conducted on women (n = 41) undergoing core-needle biopsy to diagnose suspicious breast masses.
CAMLs were found in 93% of known malignant patients (n = 38/41), averaging 19.4 cells per sample, but none in the healthy controls. In subjects undergoing core biopsy for initial diagnosis, CAMLs were found in 88% of subjects with invasive carcinoma (n = 15/17) and 26% with benign breast conditions (n = 5/19).
These preliminary pilot studies suggest that the presence of CAMLs may differentiate patients with malignant disease, benign breast conditions, and healthy individuals.
We supply evidence that this previously unidentified circulating stromal cell may have utility as a screening tool to detect breast cancer in various malignancies, irrespective of disease stage. Cancer Epidemiol Biomarkers Prev; 25(7); 1037-42. ©2016 AACR.
基于血液的检测可作为一种非侵入性方法,用于回收和分析循环肿瘤衍生细胞以供临床使用。循环癌相关巨噬细胞样细胞(CAML)是在外周血中发现的特殊髓样细胞,与实体恶性肿瘤的存在相关。我们前瞻性地检测外周血中的CAML,以确定其在临床表现时与乳腺疾病状态相关的患病率、特异性和敏感性。
我们报告两项相关但独立的研究:1)使用细胞筛微滤器从已知恶性疾病患者(n = 41)的血样中分离CAML。将患病率和特异性与健康志愿者(n = 16)进行比较。2)对接受粗针活检以诊断可疑乳腺肿块的女性(n = 41)进行了一项后续双盲试点研究。
在93%的已知恶性患者(n = 38/41)中发现了CAML,每个样本平均有19.4个细胞,但在健康对照中未发现。在接受初次诊断的粗针活检的受试者中,88%的浸润性癌患者(n = 15/17)和26%的良性乳腺疾病患者(n = 5/19)中发现了CAML。
这些初步试点研究表明,CAML的存在可能区分恶性疾病患者、良性乳腺疾病患者和健康个体。
我们提供的证据表明,这种先前未被识别的循环基质细胞可能作为一种筛查工具,用于检测各种恶性肿瘤中的乳腺癌,而不论疾病阶段如何。《癌症流行病学、生物标志物与预防》;25(7);1037 - 42。©2016美国癌症研究协会。